Schrodinger has created a platform for modelling and simulation of small and macromolecules, lead discovery and optimisation and visualisation and automation.
The software allows users to predict the effects of compounds. Using the funding boost Schrodinger will “pursue a number of research and development projects” to improve its computer-aided drug design offering.
“This investment represents an important validation as well as a significant opportunity for us”, added Ramy Farid, president of Schrödinger.
The funding came from Cascade Investment, a company wholly owned by Microsoft co-founder Bill Gates.